<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN" "JATS-journalpublishing1-4.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.4" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">ojem</journal-id>
      <journal-title-group>
        <journal-title>Open Journal of Emergency Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2332-1814</issn>
      <issn pub-type="ppub">2332-1806</issn>
      <publisher>
        <publisher-name>Scientific Research Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.4236/ojem.2026.142009</article-id>
      <article-id pub-id-type="publisher-id">ojem-151762</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
        <subj-group>
          <subject>Medicine</subject>
          <subject>Healthcare</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Behavioural Shift as a Subtle Mental Change Occurring in a Case of Rheumatoid Arthritis Experiencing Zoster Encephalitis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thadeshwar</surname>
            <given-names>Shweta</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Upadhyaya</surname>
            <given-names>Shiksha</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">0000-0002-4585-2093</contrib-id>
          <name name-style="western">
            <surname>Pavrey</surname>
            <given-names>Renaldo</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> Department of Internal Medicine, Nanavati Max Super Specialty Hospital &amp; Medical Research Centre, Mumbai, India </aff>
      <aff id="aff2"><label>2</label> Centre for Accident and Emergency Medicine, Nanavati Max Super Specialty Hospital &amp; Medical Research Centre, Mumbai, India </aff>
      <author-notes>
        <fn fn-type="conflict" id="fn-conflict">
          <p>The authors declare no conflicts of interest regarding the publication of this paper.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>06</month>
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>06</month>
        <year>2026</year>
      </pub-date>
      <volume>14</volume>
      <issue>02</issue>
      <fpage>110</fpage>
      <lpage>116</lpage>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>12</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>06</month>
          <year>2026</year>
        </date>
        <date date-type="published">
          <day>08</day>
          <month>06</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2026 by the authors and Scientific Research Publishing Inc.</copyright-statement>
        <copyright-year>2026</copyright-year>
        <license license-type="open-access">
          <license-p> This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link> ). </license-p>
        </license>
      </permissions>
      <self-uri content-type="doi" xlink:href="https://doi.org/10.4236/ojem.2026.142009">https://doi.org/10.4236/ojem.2026.142009</self-uri>
      <abstract>
        <p>Primary varicella (chickenpox) and herpes zoster (shingles) are caused by the highly contagious varicella zoster virus (VZV). Due to underlying immunological dysfunction, people with rheumatoid arthritis (RA) may be more vulnerable to serious infection. A 52-year-old woman with rheumatoid arthritis, who was receiving hydroxychloroquine and sulfasalazine, is the subject of our case study. She had a broad vesicular rash, subtle cognitive difficulties, and VZV hepatitis, a known complication of disseminated infection. Through positive immunoglobulin M (IgM), immunoglobulin G (IgG), and polymerase chain reaction (PCR) detection of VZV deoxyribonucleic acid (DNA) in blood and cerebrospinal fluid (CSF), laboratory studies verified the spread of VZV. Our case highlights behavioral shift as a unique presentation of VZV encephalopathy. An interdisciplinary approach continues to be important in the management of such complicated cases, with timely interventions and better outcomes.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated" xml:lang="en">
        <kwd>Cognitive Change</kwd>
        <kwd>Behavioural Shift</kwd>
        <kwd>Encephalitis</kwd>
        <kwd>Varicella Zoster</kwd>
        <kwd>Emergency Department</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <p>Varicella-zoster virus (VZV) is an extremely contagious, neurotropic human herpes virus that causes primary varicella (chickenpox) and herpes zoster (shingles). Although varicella is in most cases a mild, self-limiting illness in immune-competent humans, reactivation of VZV in the immune-compromised patient is associated with possible severe complications like disseminated infection, encephalitis, and hepatitis. Disseminated VZV is defined as extensive cutaneous lesions outside of the normal dermatome pattern plus visceral organ participation, necessitating prompt medical consultation [<xref ref-type="bibr" rid="B1">1</xref>].</p>
      <p>It has been postulated that defects in innate and adaptive immunity due to RA could increase susceptibility to viral reactivation [<xref ref-type="bibr" rid="B2">2</xref>]. VZV encephalitis is a severe, but rare complication of disseminated VZV infection. Although mental changes in VZV encephalopathy are usually a given (eg., confusion, seizures, altered consciousness, memory loss, speech problems, and focal neurologic deficits), it is still relatively rare for such patients to manifest subtle behavioral and cognitive shifts (like emotional labiality, personality shifts, and disorganized thinking) as the only presentation to the Emergency Department [<xref ref-type="bibr" rid="B3">3</xref>][<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>This case report underscores the need to have a high index of suspicion for disseminated VZV in immune-compromised hosts with unusual symptoms. Early diagnosis, aggressive antiviral therapy, and an interdisciplinary treatment approach are critical in treating this potentially lethal disease.</p>
    </sec>
    <sec id="sec2">
      <title>2. Case Presentation</title>
      <p>A 52-year-old woman came to the Emergency Department (ED) complaining of fever, malaise, and a generalized vesicular rash that began on her face, and quickly progressed to her trunk and extremities within a few days. She complained of severe headaches; subtle abnormal behaviour with involuntary movement of hands and lips, with intermittent agitation were noted by the husband.</p>
      <p>Her past medical history was notable for rheumatoid arthritis (RA), for which she had been treated with hydroxychloroquine and sulfasalazine for many years. She had no history of herpes zoster, or varicella vaccination. There was no history of recent exposure to people with active varicella infection, or herpes zoster.</p>
      <fig id="fig1">
        <label>Figure 1</label>
        <graphic xlink:href="https://html.scirp.org/file/1750353-rId15.jpeg?20260608090403" />
      </fig>
      <p><bold>Figure 1</bold><bold>.</bold> Vesicular lesions in different stages of healing over the face.</p>
      <p>On physical exam, she was febrile (38.7˚C), disoriented to place and time, and had scattered vesicular lesions at different stages of healing on her body; including the face, trunk, and limbs (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>). Neurological exam showed mild neck stiffness, but no focal deficit. She was conscious and interacting with the physicians, however, she was unable to answer beyond simple questions, or perform complex tasks. Her Glasgow Coma Scale was E4V4M6. The Mini Mental State Exam score was 22. The abdomen was tender in the right upper quadrant, and scleral icterus was present.</p>
      <fig id="fig2">
        <label>Figure 2</label>
        <graphic xlink:href="https://html.scirp.org/file/1750353-rId16.jpeg?20260608090403" />
      </fig>
      <p><bold>Figure 2</bold><bold>.</bold> Healed scabs over the trunk.</p>
      <p>She was admitted for further evaluation, and initial laboratory (<bold>Table 1</bold>) and imaging studies were ordered to assess the extent of systemic involvement, and confirm the diagnosis of disseminated VZV infection. Given her altered mental status and immune-compromised state, a lumbar puncture, and neuroimaging were performed.</p>
      <p><bold>Table 1</bold><bold>.</bold> Relevant laboratory results including blood and cerebrospinal fluid analysis.</p>
      <table-wrap id="tbl1">
        <label>Table 1</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>No.</bold>
              </td>
              <td>
                <bold>Laboratory Test</bold>
              </td>
              <td>
                <bold>Result</bold>
              </td>
              <td>
                <bold>Reference Range</bold>
              </td>
            </tr>
            <tr>
              <td>1.</td>
              <td>Varicella Zoster (VZV) IgM</td>
              <td>&gt; 2.30 ISR</td>
              <td>&lt; 0.90 - 1.1 ISR</td>
            </tr>
            <tr>
              <td>2.</td>
              <td>Varicella Zoster (VZV) IgG</td>
              <td>695 mIU/ml</td>
              <td>&lt; 50 - 100 mIU/ml</td>
            </tr>
            <tr>
              <td>3.</td>
              <td>VZV DNA (in blood)</td>
              <td>Positive</td>
              <td>Qualitative</td>
            </tr>
            <tr>
              <td>4.</td>
              <td>VZV DNA (in spinal fluid)</td>
              <td>Positive</td>
              <td>Qualitative</td>
            </tr>
            <tr>
              <td>5.</td>
              <td>Alanine aminotransferase</td>
              <td>303 U/L</td>
              <td>7 - 56 U/L</td>
            </tr>
            <tr>
              <td>6.</td>
              <td>Aspartate aminotransferase</td>
              <td>249 U/L</td>
              <td>8 - 45 U/L</td>
            </tr>
            <tr>
              <td>7.</td>
              <td>Alkaline phosphatase</td>
              <td>231 U/L</td>
              <td>44 - 147 U/L</td>
            </tr>
            <tr>
              <td>8.</td>
              <td>Gamma-glutamyl transferase</td>
              <td>406 U/L</td>
              <td>5 - 40 U/L</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="sec3">
      <title>3. Management and Outcome</title>
      <p>The patient was started on intravenous acyclovir 10 mg/kg every eight hours to treat the VZV infection. Supportive care, such as intravenous fluids, electrolyte balance, and antipyretics, was initiated. Due to her hepatic involvement, liver function tests were monitored closely, and a hepatology consultation was obtained. She was also initiated on prophylactic proton-pump inhibitors to avoid stress-related mucosal injury.</p>
      <p>Neurology and infectious diseases teams took care of her, because there was fear of VZV encephalitis. Lumbar puncture was performed, with findings of cerebrospinal fluid analysis as described (<bold>Table 2</bold>); PCR detected the presence of VZV DNA in cerebrospinal fluid. Brain magnetic resonance imaging (MRI) did not show hemorrhage or ischemia.</p>
      <p><bold>Table 2</bold><bold>.</bold> General examination of cerebrospinal fluid.</p>
      <table-wrap id="tbl2">
        <label>Table 2</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>General Examination (CSF)</bold>
              </td>
              <td>
                <bold>Result</bold>
              </td>
              <td>
                <bold>Reference Range</bold>
              </td>
            </tr>
            <tr>
              <td>Volume</td>
              <td>10 ml</td>
              <td>
              </td>
            </tr>
            <tr>
              <td>Appearance</td>
              <td>Clear</td>
              <td>
              </td>
            </tr>
            <tr>
              <td>Colour</td>
              <td>Colourless</td>
              <td>
              </td>
            </tr>
            <tr>
              <td>Clot/Clot Web</td>
              <td>Absent</td>
              <td>
              </td>
            </tr>
            <tr>
              <td>pH</td>
              <td>8.5</td>
              <td>7.35 - 7.44</td>
            </tr>
            <tr>
              <td>Chemical Examination</td>
              <td>
              </td>
              <td>
              </td>
            </tr>
            <tr>
              <td>COB - WEB</td>
              <td>Absent</td>
              <td>
              </td>
            </tr>
            <tr>
              <td>CSF Sugar</td>
              <td>70.5</td>
              <td>40 - 80</td>
            </tr>
            <tr>
              <td>CSF Protein</td>
              <td>33.8</td>
              <td>20 - 40</td>
            </tr>
            <tr>
              <td>Microscopic examination</td>
              <td>
              </td>
              <td>
              </td>
            </tr>
            <tr>
              <td>Erythrocytes</td>
              <td>No cells seen</td>
              <td>
              </td>
            </tr>
            <tr>
              <td>Nucleated cells</td>
              <td>No cells seen</td>
              <td>
              </td>
            </tr>
            <tr>
              <td>Polymorphs</td>
              <td>No cells seen</td>
              <td>
              </td>
            </tr>
            <tr>
              <td>Lymphocyte</td>
              <td>No cells seen</td>
              <td>
              </td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>During her hospitalization, her mental status normalized progressively, with crusting of the vesicular lesions. Her liver function tests became normal within two weeks, and she was hemodynamically stable. As per standard local protocol, she was switched to oral valacyclovir after 14 days of intravenous acyclovir for an additional 10-day course.</p>
    </sec>
    <sec id="sec4">
      <title>4. Discussion</title>
      <p>Disseminated VZV is a severe disease primarily seen in immune-compromised hosts, such as patients with rheumatoid arthritis, human immunodeficiency virus infection, cancer, or those on immunosuppressive therapy. Below, we have summarized the potential mechanisms correlating rheumatoid arthritis [<xref ref-type="bibr" rid="B3">3</xref>] to an immune-compromised state (<bold>Table 3</bold>). </p>
      <p><bold>Table 3</bold><bold>.</bold> Mechanisms resulting in an immune-compromised state in rheumatoid arthritis.</p>
      <table-wrap id="tbl3">
        <label>Table 3</label>
        <table>
          <tbody>
            <tr>
              <td>
                <bold>Mechanism</bold>
              </td>
              <td>
                <bold>Effect on Immune Status</bold>
              </td>
            </tr>
            <tr>
              <td>Chronic autoimmunity</td>
              <td>Immune dysregulation and altered host defence</td>
            </tr>
            <tr>
              <td>Intrinsic immune defects</td>
              <td>Impaired cell-mediated responses</td>
            </tr>
            <tr>
              <td>Comorbidities &amp; lifestyle</td>
              <td>Additional infection risk factors</td>
            </tr>
            <tr>
              <td>Immunosuppressive therapy</td>
              <td>Iatrogenic immune-compromise</td>
            </tr>
            <tr>
              <td>Clinical outcomes</td>
              <td>Elevated risk of infections</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>VZV encephalitis is the most dreaded of disseminated VZV complications, as it can cause severe neurological impairment and high mortality, if left untreated. It also occurs primarily in elderly or immune-compromised patients. The diagnosis is often delayed; risk factors for unfavourable outcome are age, cerebral vasculitis, and Glasgow Coma Scale score &lt; 15 [<xref ref-type="bibr" rid="B5">5</xref>]. The mechanism of pathogenesis includes viral reactivation in the dorsal root ganglia with subsequent spread to the central nervous system. This leads to inflammation, neuronal damage, and, in some instances, vasculopathy causing strokes [<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>Psychiatric symptoms, seen as subtle mental changes in our patient, can be associated with systemic and central nervous system infection and they can be the initial presenting symptoms, occurring in the absence of neurological symptoms. A 2001 study done by Caroff <italic>et al</italic><italic>.</italic> reported delusions, hallucinations and affective disorders as the initial symptoms, although it is possible that the hallucinations can be attributed to the febrile nature of the illness [<xref ref-type="bibr" rid="B5">5</xref>]. According to a comprehensive review by Hokkanen L <italic>et al</italic><italic>.</italic> most patients with cognitive decline due to Herpes Zoster encephalitis eventually returned to their prior cognitive status provided they received timely treatment. However, persisting cognitive symptoms such as memory impairment, dysphasia, difficulty in interpreting proverbs, and, in some cases, dementia have been reported. Neuropsychiatric symptoms such as psychosis, irritability and affect labiality ranging from euphoria to dysphoria have frequently been described both at the acute stage and as residual symptoms [<xref ref-type="bibr" rid="B6">6</xref>]. In our case, early detection and vigorous antiviral treatment avoided severe neurologic deterioration.</p>
      <p>Untreated VZV encephalitis carries a high mortality rate, stressing the urgency of early treatment. According to a study by Venkatesan <italic>et al.</italic> (2013), systemic treatment of encephalitis in the form of early empirical antiviral therapy until confirmatory test results are available is advocated [<xref ref-type="bibr" rid="B7">7</xref>]. Our case followed suit, illustrating the urgency of an early initiation of acyclovir. The role of adjunctive therapy in disseminated VZV is uncertain. Although corticosteroids have been found to decrease inflammation in some viral encephalitis, corticosteroid use in VZV is controversial secondary to the fear of exacerbating viral replication [<xref ref-type="bibr" rid="B8">8</xref>]. In some cases, intravenous immunoglobulin (IVIG) has been suggested to benefit immune-compromised patients with fulminant VZV infections, although this is based on limited studies (Merck Manual) [<xref ref-type="bibr" rid="B9">9</xref>].</p>
      <p>Vaccination is the most effective measure against VZV complications. The recombinant zoster vaccine (RZV) has been effective in preventing herpes zoster and its complications, even in immune-compromised patients [<xref ref-type="bibr" rid="B10">10</xref>]. Our patient was recommended to get vaccinated after recovery, to minimize the chances of reactivation of VZV in the future.</p>
    </sec>
    <sec id="sec5">
      <title>5. Conclusion</title>
      <p>This case highlights the need to consider disseminated varicella zoster virus (VZV) infection as a serious complication in immune-compromised patients, including those with rheumatoid arthritis (RA). Although not on a biologic immunosuppressant, our patient showed profound immune dysfunction, which emphasizes the need for increased awareness in such patients. Early detection and timely institution of antiviral therapy with intravenous acyclovir were important in avoiding further complications, especially encephalitis and hepatic impairment.</p>
    </sec>
    <sec id="sec6">
      <title>Key Takeaways</title>
      <p>Immune dysregulation in rheumatoid arthritis, even if not an active immune-suppression, poses a significant risk in the development of varicella zoster dissemination.Subtle behavioural shifts and cognitive difficulties can often be the only presenting symptoms hinting towards VZV encephalopathy.</p>
    </sec>
    <sec id="sec7">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. Patient confidentiality and anonymity have been maintained.</p>
    </sec>
    <sec id="sec8">
      <title>Funding</title>
      <p>No funding was received for this work.</p>
    </sec>
    <sec id="sec9">
      <title>List of Abbreviations</title>
      <table-wrap id="tbl4">
        <label>Table 4</label>
        <table>
          <tbody>
            <tr>
              <td>VZV</td>
              <td>Varicella Zoster Virus</td>
            </tr>
            <tr>
              <td>RA</td>
              <td>Rheumatoid Arthritis</td>
            </tr>
            <tr>
              <td>IgM</td>
              <td>Immunoglobulin M</td>
            </tr>
            <tr>
              <td>IgG</td>
              <td>Immunoglobulin G</td>
            </tr>
            <tr>
              <td>PCR</td>
              <td>Polymerase Chain Reaction</td>
            </tr>
            <tr>
              <td>DNA</td>
              <td>Deoxyribonucleic Acid</td>
            </tr>
            <tr>
              <td>CSF</td>
              <td>Cerebrospinal Fluid</td>
            </tr>
            <tr>
              <td>MRI</td>
              <td>Magnetic Resonance Imaging</td>
            </tr>
            <tr>
              <td>ED</td>
              <td>Emergency Department</td>
            </tr>
            <tr>
              <td>IVIG</td>
              <td>Intravenous Immunoglobulin</td>
            </tr>
            <tr>
              <td>RZV</td>
              <td>Recombinant Zoster Vaccine</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Lizzi, J., Hill, T. and Jakubowski, J. (2019) Varicella Zoster Virus Encephalitis. <italic>Clinical</italic><italic>Practice</italic><italic>and</italic><italic>Cases</italic><italic>in</italic><italic>Emergency</italic><italic>Medicine</italic>, 3, 380-382. https://doi.org/10.5811/cpcem.2019.8.43010 <pub-id pub-id-type="doi">10.5811/cpcem.2019.8.43010</pub-id><pub-id pub-id-type="pmid">31763593</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5811/cpcem.2019.8.43010">https://doi.org/10.5811/cpcem.2019.8.43010</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Lizzi, J.</string-name>
              <string-name>Hill, T.</string-name>
              <string-name>Jakubowski, J.</string-name>
            </person-group>
            <year>2019</year>
            <article-title>Varicella Zoster Virus Encephalitis</article-title>
            <source>Clinical Practice and Cases in Emergency Medicine</source>
            <volume>3</volume>
            <pub-id pub-id-type="doi">10.5811/cpcem.2019.8.43010</pub-id>
            <pub-id pub-id-type="pmid">31763593</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Thomas, S.L. and Hall, A.J. (2004) What Does Epidemiology Tell Us about Risk Factors for Herpes Zoster? <italic>The</italic><italic>Lancet</italic><italic>Infectious</italic><italic>Diseases</italic>, 4, 26-33. https://doi.org/10.1016/s1473-3099(03)00857-0 <pub-id pub-id-type="doi">10.1016/s1473-3099(03)00857-0</pub-id><pub-id pub-id-type="pmid">14720565</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s1473-3099(03)00857-0">https://doi.org/10.1016/s1473-3099(03)00857-0</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Thomas, S.L.</string-name>
              <string-name>Hall, A.J.</string-name>
            </person-group>
            <year>2004</year>
            <article-title>What Does Epidemiology Tell Us about Risk Factors for Herpes Zoster? The Lancet Infectious Diseases, 4, 26-33</article-title>
            <volume>3099</volume>
            <issue>03</issue>
            <pub-id pub-id-type="doi">10.1016/s1473-3099(03)00857-0</pub-id>
            <pub-id pub-id-type="pmid">14720565</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Listing, J., Gerhold, K. and Zink, A. (2013) The Risk of Infections Associated with Rheumatoid Arthritis, with Its Comorbidity and Treatment. <italic>Rheumatology</italic>, 52, 53-61. https://doi.org/10.1093/rheumatology/kes305 <pub-id pub-id-type="doi">10.1093/rheumatology/kes305</pub-id><pub-id pub-id-type="pmid">23192911</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/rheumatology/kes305">https://doi.org/10.1093/rheumatology/kes305</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Listing, J.</string-name>
              <string-name>Gerhold, K.</string-name>
              <string-name>Zink, A.</string-name>
            </person-group>
            <year>2013</year>
            <article-title>The Risk of Infections Associated with Rheumatoid Arthritis, with Its Comorbidity and Treatment</article-title>
            <source>Rheumatology</source>
            <volume>52</volume>
            <pub-id pub-id-type="doi">10.1093/rheumatology/kes305</pub-id>
            <pub-id pub-id-type="pmid">23192911</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Herlin, L.K., Hansen, K.S., Bodilsen, J., Larsen, L., Brandt, C., Andersen, C.Ø., <italic>et al</italic>. (2020) Varicella Zoster Virus Encephalitis in Denmark from 2015 to 2019—A Nationwide Prospective Cohort Study. <italic>Clinical</italic><italic>Infectious</italic><italic>Diseases</italic>, 72, 1192-1199. https://doi.org/10.1093/cid/ciaa185 <pub-id pub-id-type="doi">10.1093/cid/ciaa185</pub-id><pub-id pub-id-type="pmid">32103249</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciaa185">https://doi.org/10.1093/cid/ciaa185</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Herlin, L.K.</string-name>
              <string-name>Hansen, K.S.</string-name>
              <string-name>Bodilsen, J.</string-name>
              <string-name>Larsen, L.</string-name>
              <string-name>Brandt, C.</string-name>
              <string-name>Andersen, C.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Varicella Zoster Virus Encephalitis in Denmark from 2015 to 2019—A Nationwide Prospective Cohort Study</article-title>
            <source>Clinical Infectious Diseases</source>
            <volume>72</volume>
            <pub-id pub-id-type="doi">10.1093/cid/ciaa185</pub-id>
            <pub-id pub-id-type="pmid">32103249</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Caroff, S.N., Mann, S.C., Gliatto, M.F., Sullivan, K.A. and Campbell, E.C. (2001) Psychiatric Manifestations of Acute Viral Encephalitis. <italic>Psychiatric</italic><italic>Annals</italic>, 31, 193-204. https://doi.org/10.3928/0048-5713-20010301-10 <pub-id pub-id-type="doi">10.3928/0048-5713-20010301-10</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3928/0048-5713-20010301-10">https://doi.org/10.3928/0048-5713-20010301-10</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Caroff, S.N.</string-name>
              <string-name>Mann, S.C.</string-name>
              <string-name>Gliatto, M.F.</string-name>
              <string-name>Sullivan, K.A.</string-name>
              <string-name>Campbell, E.C.</string-name>
            </person-group>
            <year>2001</year>
            <article-title>Psychiatric Manifestations of Acute Viral Encephalitis</article-title>
            <source>Psychiatric Annals</source>
            <volume>31</volume>
            <pub-id pub-id-type="doi">10.3928/0048-5713-20010301-10</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Hokkanen, L. and Launes, J. (2000) Cognitive Outcome in Acute Sporadic Encephalitis. <italic>Neuropsychology</italic><italic>Review</italic>, 10, 151-167. https://doi.org/10.1023/a:1009079531196 <pub-id pub-id-type="doi">10.1023/a:1009079531196</pub-id><pub-id pub-id-type="pmid">10983899</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1023/a:1009079531196">https://doi.org/10.1023/a:1009079531196</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Hokkanen, L.</string-name>
              <string-name>Launes, J.</string-name>
            </person-group>
            <year>2000</year>
            <article-title>Cognitive Outcome in Acute Sporadic Encephalitis</article-title>
            <source>Neuropsychology Review</source>
            <volume>10</volume>
            <fpage>100907</fpage>
            <pub-id pub-id-type="doi">10.1023/a:1009079531196</pub-id>
            <pub-id pub-id-type="pmid">10983899</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Venkatesan, A., Tunkel, A.R., Bloch, K.C., Lauring, A.S., Sejvar, J., Bitnun, A., <italic>et al</italic>. (2013) Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium. <italic>Clinical</italic><italic>Infectious</italic><italic>Diseases</italic>, 57, 1114-1128. https://doi.org/10.1093/cid/cit458 <pub-id pub-id-type="doi">10.1093/cid/cit458</pub-id><pub-id pub-id-type="pmid">23861361</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/cit458">https://doi.org/10.1093/cid/cit458</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Venkatesan, A.</string-name>
              <string-name>Tunkel, A.R.</string-name>
              <string-name>Bloch, K.C.</string-name>
              <string-name>Lauring, A.S.</string-name>
              <string-name>Sejvar, J.</string-name>
              <string-name>Bitnun, A.</string-name>
              <string-name>Definitions, D</string-name>
            </person-group>
            <year>2013</year>
            <article-title>Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium</article-title>
            <source>Clinical Infectious Diseases</source>
            <volume>57</volume>
            <pub-id pub-id-type="doi">10.1093/cid/cit458</pub-id>
            <pub-id pub-id-type="pmid">23861361</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Vangiliappan, K., Venkatraman, C., Samivel, B., Lakshmi Narasimhan, R. and Govindarajan, S. (2019) A Study on Neurological Manifestations of Primary Varicella Zoster Virus Infection. <italic>Neurology Asia</italic>, 24, 9-14.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Vangiliappan, K.</string-name>
              <string-name>Venkatraman, C.</string-name>
              <string-name>Samivel, B.</string-name>
              <string-name>Narasimhan, R.</string-name>
              <string-name>Govindarajan, S.</string-name>
            </person-group>
            <year>2019</year>
            <article-title>A Study on Neurological Manifestations of Primary Varicella Zoster Virus Infection</article-title>
            <source>Neurology Asia</source>
            <volume>24</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <citation-alternatives>
          <mixed-citation publication-type="book">Kaye, K.M. (2026) Chickenpox. Merck Manual Professional Edition: Merck Manual. https://www.merckmanuals.com/professional/infectious-diseases/herpesviruses/chickenpox</mixed-citation>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <string-name>Kaye, K.M.</string-name>
            </person-group>
            <year>2026</year>
            <article-title>Chickenpox</article-title>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Alvarez, J.C., Alvarez, J., Ticono, J., Medallo, P., Miranda, H., Ferrés, M., <italic>et al</italic>. (2020) Varicella-Zoster Virus Meningitis and Encephalitis: An Understated Cause of Central Nervous System Infections. <italic>Cureus</italic>, 12, e11583. https://doi.org/10.7759/cureus.11583 <pub-id pub-id-type="doi">10.7759/cureus.11583</pub-id><pub-id pub-id-type="pmid">33364107</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7759/cureus.11583">https://doi.org/10.7759/cureus.11583</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Alvarez, J.C.</string-name>
              <string-name>Alvarez, J.</string-name>
              <string-name>Ticono, J.</string-name>
              <string-name>Medallo, P.</string-name>
              <string-name>Miranda, H.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Varicella-Zoster Virus Meningitis and Encephalitis: An Understated Cause of Central Nervous System Infections</article-title>
            <source>Cureus</source>
            <volume>12</volume>
            <pub-id pub-id-type="doi">10.7759/cureus.11583</pub-id>
            <pub-id pub-id-type="pmid">33364107</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>